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Abstract
Purpose The aim of this study was to evaluate the cost
effectiveness of ranibizumab compared with verteporfin
photodynamic therapy (vPDT) or no treatment (observa-
tion) in patients with visual impairment due to myopic
choroidal neovascularization (CNV).
Methods A Markov model with health states defined by
best-corrected visual acuity and a 3-month cycle length
was developed. It had a healthcare provider (UK National
Health Service and personal social services) perspective, a
lifetime time horizon, and was based on 2011 prices; future
costs and health outcomes were discounted at 3.5 % per
annum. Baseline characteristics were based on the phase III
RADIANCE (Ranibizumab and vPDT Evaluation in
Myopic CNV) study, and year 1 health-state transitions
were based on this and the VIP (Verteporfin in Photody-
namic Therapy) study. Extensive sensitivity analyses tested
the robustness of the model.
Results The lifetime cost of treating myopic CNV with
ranibizumab was £12,866, whereas vPDT and observation
were associated with total costs of £14,421 and £8,163,
respectively. Ranibizumab treatment produced higher
cumulative quality-adjusted life-years (QALYs; 12.99)
than vPDT (12.60) or observation (12.45). Ranibizumab
treatment was therefore dominant, with greater health gains
and lower overall costs than vPDT. Ranibizumab was cost
effective compared with observation, with an incremental
cost-effectiveness ratio of £8,778/QALY. In the probabi-
listic sensitivity analysis, ranibizumab had a 100 % and
88 % probability of being cost effective compared with
vPDT and observation, respectively, at a willingness-to-
pay threshold of £20,000/QALY.
Conclusion This study indicates that ranibizumab therapy
is dominant over vPDT for the treatment of visual
impairment due to CNV secondary to pathologic myopia in
the UK healthcare setting and cost effective compared with
observation.
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Key Points
Ranibizumab is a vascular endothelial growth factor
A inhibitor licensed for the treatment of visual
impairment due to choroidal neovascularization
(CNV) secondary to pathologic myopia.
A cost-utility model was developed using the pivotal
phase III RADIANCE study results. This indicated
that the health gains associated with ranibizumab
treatment over a patient’s lifetime are higher than
those associated with the previous standard of care,
verteporfin photodynamic therapy (vPDT), or
managing patients through observation.
Ranibizumab treatment was associated with lower
lifetime costs than vPDT and is therefore an
economically dominant alternative to vPDT for the
treatment of myopic CNV in the UK healthcare
setting. Ranibizumab treatment is cost effective
compared with observation.
1 Introduction
Pathologic myopia is a progressive condition characterized
by axial elongation and degenerative changes in the posterior
segment of the eye [1]. Choroidal neovascularization (CNV)
is characterized by the growth of blood vessels under the
retinal pigment epithelium or retina; these vessels can rup-
ture, leading to the accumulation of blood and fluid within
layers of the retina [2]. CNV secondary to pathologic myopia,
also known as myopic CNV, is one of the major causes of
blindness and visual impairment worldwide [3, 4].
Verteporfin (Visudyne, Novartis Pharma AG, Swit-
zerland) photodynamic therapy (vPDT) has replaced laser
photocoagulation as the treatment of choice for myopic
CNV for subfoveal lesions [3]. However, vPDT does not
significantly improve patients’ vision and may not control
the underlying neovascularization disease activity [5, 6]. In
the 24-month Verteporfin in Photodynamic Therapy (VIP)
trial, the proportion of patients whose best-corrected visual
acuity (BCVA) remained stable was higher with vPDT than
with placebo at 12 months (72 vs 44 %, p \ 0.01), but this
was no longer significant at 24 months (64 vs 49 %,
p = 0.11) [5]. The median change in BCVA from baseline
to 24 months ranged from -1 to 1 letter with vPDT and -5
to -9 letters with placebo (measured using the ETDRS
[Early Treatment Diabetic Retinopathy Study] chart).
There is therefore an unmet need for treatment that
improves vision in patients with visual impairment sec-
ondary to myopic CNV.
Ranibizumab (Lucentis, Novartis Pharma AG, Swit-
zerland) is a recombinant, humanized, monoclonal anti-
body fragment designed to inhibit the active forms of
vascular endothelial growth factor A (VEGF-A) [7].
VEGF-A is important in the pathogenesis of CNV, stimu-
lating the growth of new blood vessels and increasing
vascular leakage [8, 9]. Ranibizumab has demonstrated
clinical efficacy in patients with visual impairment sec-
ondary to wet age-related macular degeneration [10–12],
diabetic macular oedema [13–17] and macular oedema
following retinal vein occlusion [18–22], and is widely
licensed and reimbursed across these indications. The most
recent indication is for the treatment of visual impairment
due to CNV secondary to pathologic myopia.
The RADIANCE (Ranibizumab and vPDT Evaluation in
Myopic CNV) study was a 12-month, phase III study in which
patients were randomized to either ranibizumab or vPDT,
plus appropriate shams [23]. To avoid denying patients an
effective treatment, patients randomized to vPDT could
switch to ranibizumab from month 3 onwards at the treating
investigator’s discretion. Indeed, 73 % (40/55) of patients
randomized to vPDT did switch to ranibizumab during the
study, including two patients who switched before month 3.
The primary endpoint, the mean average change from base-
line in BCVA at 3 months, was ?10.5 and ?10.6 letters in
patients randomized to ranibizumab (administered according
to disease stabilization or disease activity criteria, respec-
tively) compared with ?2.2 letters in the vPDT group
(p \ 0.0001 versus ranibizumab, stratified Cochran–Mantel–
Haenszel test) [23]. Improvements in BCVA in the rani-
bizumab groups were sustained for the duration of the study.
Patient-reported visual functioning, as measured by the
25-item National Eye Institute Visual Functioning Ques-
tionnaire (NEI VFQ-25), was improved in the ranibizumab
groups from baseline and the difference compared with vPDT
was significant at 3 months (measured using the composite
score, p \ 0.05 [24]).
Here we present an economic analysis of ranibizumab in
the treatment of visual impairment due to myopic CNV. We
have used a Markov health-state transition model and have
incorporated findings from the RADIANCE study and VIP
trial to compare the costs and benefits of treating patients with
ranibizumab with those of vPDT treatment or observation
only, adopting a UK healthcare provider perspective.
2 Methods
2.1 Model Structure
A Markov decision-analytical model was developed to
predict the long-term costs and health outcomes of rani-
bizumab treatment for visual impairment due to myopic
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CNV compared with vPDT or observation only. In the
Markov structure, patients were categorized by health state
and could move between states at the end of each 3-month
cycle according to their level of visual acuity. Half-cycle
correction was used. The model had eight health states
defined by the BCVA in the treated eye and a ninth
absorbing death state (Fig. 1). The BCVA health states are
defined by 10-letter (two-line) BCVA ranges between 25
letters or less and 86–100 letters (on the ETDRS chart). A
10-letter gain is associated with clinically relevant changes
in the patient’s vision and vision-related quality of life
[25].
BCVA scores at baseline were taken from the RADI-
ANCE study (treated eyes of patients receiving rani-
bizumab by disease activity criterion, full analysis set). The
starting age of patients was 55 years based on the mean age
of patients in the RADIANCE study [23] and 15 % were
assumed to have bilateral disease at the start of the model
[26, 27]. Patients received either ranibizumab or vPDT
over 2 years and treatment was resumed only in cases of
recurrence (Table 1). The annual recurrence rate was based
on expert opinion (two international advisory boards
comprising experts chosen for their high level of expertise
in retinal disease) and assumed to be 6 % following
treatment completion (consensus was reached by discus-
sion). This was a conservative estimate and is supported by
recurrence data from a long-term study in which 46 % of
eyes treated with vPDT and/or anti-VEGF experienced at
least one recurrence over a mean follow-up of 71 months
[28]. At baseline, 21 % of patients were treated in their
better-seeing eye (BSE; defined as such when the BCVA
letter score at baseline was higher than the score for the
non-study eye) [29] estimated from the RADIANCE study.
The proportion of patients treated in their BSE in each
health state is shown in Table 2. The model is dynamic in
that it allows the treated eye to change from being the
worse-seeing eye (WSE) to the BSE as BCVA improves.
This was modelled using a probability matrix of the study
eye being the BSE by level of visual acuity (Table 2).
Transition probabilities (TPs) were calculated for each
3-month cycle depending on the treatment received.
Patients could transition between any health state in each
cycle, according to their change in BCVA score over the
cycle. For the first year, patient-level data were used to
calculate separate TPs for each BCVA health state,
allowing for 64 unique TPs (8 9 8) for each 3-month time
period (see electronic supplementary material [ESM],
Online Resource 1). The 8 9 8 matrix was able to model
the ‘ceiling effect’ of gains in visual acuity, as patients with
high baseline visual acuity have less potential for
improvement than those with poor baseline vision. Con-
sequently, this method predicted the trial results more
accurately than two other methods tested (constant TPs
across all BCVA levels or constant probabilities for all
states other than the two highest health states). The base-
case TPs in each cycle in year 1 were varied in sensitivity
analysis by multiplying by a factor of 0.5–2.0.
The effect of ranibizumab, vPDT or observation on
BCVA was modelled over 1 year. Thereafter, it was
assumed that BCVA declined at the same rate irrespective
of initial treatment, according to natural history data. In the
base-case analysis, a second set of TPs was calculated
using data from the natural history study with the longest
available follow-up [30] and applied from year 2 onwards
to capture the natural decline in BCVA without treatment.
The overall probability of a patient’s vision deteriorating
over the follow-up period was converted to a monthly rate
and in turn converted into a 3-monthly probability. A
probability of all-cause mortality was included in the
model [31] and an increased mortality risk was applied
when BCVA was 55 letters or less to reflect increased
mortality in patients with BCVA below this level (relative














Definition of blindness:  35 letters




Fig. 1 Markov model of health states and possible patient transitions.
The transition probabilities were based on patients moving between
any two states, so the arrows as depicted on this schematic would
extend to all other states. The arrows have not been completed here
for every possible state to maintain legibility. BCVA best-corrected
visual acuity, ETDRS Early Treatment Diabetic Retinopathy study
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2.2 Utilities
Each BCVA health state was assigned a utility weight
dependent on whether the treated eye was the patient’s
BSE or WSE. The proportion of patients whose treated eye
was their BSE was matched to baseline BCVA in the
RADIANCE study and was modelled dynamically as
described earlier [23] (Table 2). Utility weights for the
BSE were taken from a study in which visual impairment
was simulated using specially designed contact lenses worn
by healthy volunteers from the UK and in which time
trade-off was used to assess participant’s valuation of their
health state prior to and following lens installation [33]
(Table 2). Utilities for patients treated in the WSE were not
available from the literature and various assumptions were
required. In the base-case scenario, utility weights for the
WSE were assumed to be higher than, or the same as, for
the BSE, because visual impairment in the WSE is con-
sidered less serious than visual impairment in the BSE. A
0.1 maximum difference in utility values was assumed for
Table 1 Model inputs for treatment and monitoring frequencies and data sources for baseline BCVA the base-case scenario
Time
period
Treatment BCVA data source Mean number of treatments
administered
Mean number of monitoring
visits
Year 1 Ranibizumab RADIANCE study (0–12 months)
[23]
3.5 [23] 8.5a (assumption)
vPDT RADIANCE study (0–3 months)
[23]
VIP trial (4–12 months) [5]
3.4 [5] 4.0 [48]
Observation VIP trial (0–12 months) [5] 0 4.0 [5]
Year 2 Ranibizumab Natural history [30] 1.0b (expert advice) 4.0 (assumption)
vPDT Natural history [30] 1.7 (VIP trial) [6] 4.0 [48]
Observation Natural history [30] 0 4.0 (assumption)
Year 3? Ranibizumab Natural history [30] 0b (expert advice) 0b (expert advice)
vPDT Natural history [30] 0 (VIP trial) [6] 0 (VIP trial) [6]
Observation Natural history [30] 0 4.0 (assumption)c
BCVA best-corrected visual acuity, mCNV myopic choroidal neovascularization, RADIANCE Ranibizumab and vPDT Evaluation in Myopic
Choroidal Neovascularization, SmPC Summary of Product Characteristics, VIP Verteporfin in Photodynamic Therapy, vPDT verteporfin pho-
todynamic therapy
a This is a conservative assumption; the ranibizumab SmPC states that about 5.5 monitoring visits are expected in year 1 of ranibizumab
treatment
b Expert advice was taken from an advisory board of 11 UK ophthalmologists
c For patients undergoing observation, as the disease is not actively being treated it was assumed that they will continue to be monitored up to
year 3, as their disease was unlikely to have been cured. For patients receiving treatment, in the absence of long-term data, and informed by
expert advice, it was assumed that mCNV has a limited course, requiring no monitoring visits in year 3














86–100 0 50a 0.850 0.850
76–85 4 50 0.758 0.836
66–75 20 22 0.685 0.821
56–65 33 22 0.611 0.807
46–55 20 21 0.537 0.793
36–45 13 15 0.464 0.779
26–35 9 10 0.390 0.764
B25 1 0a 0.353 0.750
Death 0 – 0.000 0.000
Utilities for the BSE were from a published study; WSE utilities were assumed to be proportional to those for the BSE [33]
BCVA best-corrected visual acuity, RADIANCE Ranibizumab and vPDT Evaluation in Myopic Choroidal Neovascularization
a Assumption, no patients were in these groups at baseline in the RADIANCE study
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the WSE between the best and worst possible BCVA health
states, as good vision in both eyes is considered ‘worth’ an
additional utility of 0.1 compared with good vision in only
one eye. This assumption was based on the National
Institute for Health and Care Excellence (NICE) Evidence
Review Group guidance issued for ranibizumab in the
treatment of visual impairment caused by macular oedema
secondary to retinal vein occlusion [34]. The WSE utility
curve was anchored at the highest BCVA health state, at
which point the utility was the same for the WSE and BSE
(ESM, Online Resource 2).
The probability that the study eye is the BSE improves
as vision improves. When the BCVA in the treated eye
improves to such an extent that it becomes the BSE, the
utility value is changed and can be lower than the utility
when the eye was the WSE (even though this appears
counterintuitive because one might predict that improving
vision would result in increased utility). For patients with
bilateral disease, utility values were assigned according to
BCVA in the BSE as health-related quality of life
(HRQoL) is driven by visual acuity in the BSE [35]. For
patients who had a recurrence, no change in visual acuity
or utility was assumed to occur from the recurrence.
Patients were assumed to experience adverse events
(AEs) based on the rates reported in the RADIANCE study
for ranibizumab [23] or the VIP trial for vPDT or obser-
vation [5] (ESM, Online Resource 3). All AEs that were
reported for five or more patients or were suspected to be
related to treatment were included. AEs were associated
with temporary reductions in utility based on published
literature or assumption (range of 0 to -0.02, see ESM,
Online Resource 3). Because timings for AEs were not
available, disutilities were calculated as one-off events per
patient and applied at entry to the model with the following
durations: conjunctival haemorrhage, 1 month; intraocular
pressure increase, 1 day; injection site reaction, 8.2 days.
In order to assess the comparability of the RADIANCE
study and VIP trial populations, baseline characteristics are
compared in Online Resource 4 and inclusion/exclusion
criteria are compared in Online Resource 5 (ESM). These
suggest that the two studies were sufficiently similar to
warrant the chosen methodology.
2.3 Costs
A full breakdown of costs and sources is given in ESM,
Online Resource 6. A UK healthcare provider (National
Health Service [NHS] and personal social services [PSS])
perspective was adopted, and a lifetime time horizon used.
Future costs and health outcomes were discounted at 3.5 %
per annum according to NICE recommendations. Costs
from earlier years were inflated to 2011 prices using the
Hospital and Community Services Inflation Index [36]. The
health-state costs included cost of treatment, administra-
tion, monitoring, management of AEs and recurrences, and
the long-term cost of blindness. The costs of drug acqui-
sition did not include the ranibizumab patient access
scheme discount that is in place in the UK. The cost of
administration included the cost of optical coherence
tomography plus an injection visit for ranibizumab or an
ophthalmologist consultation visit for vPDT. Frequencies
of treatment and monitoring were taken from the RADI-
ANCE study or VIP trial (Table 1). The frequency of
treatment and the cost and frequency of monitoring were
varied extensively in sensitivity analyses. For patients with
recurrence, the numbers of treatment and monitoring visits
were assumed to correspond to those for year 1 of initial
treatment. For patients with bilateral disease, the cost of
treatment and monitoring visits was doubled since the
fellow eye would incur additional treatment and monitor-
ing visits. The cost of blindness was included when the
BSE had a BCVA below 35 letters (that is, both eyes were
affected). Resource utilization was based on published data
[37] and was higher in the year following diagnosis than in
subsequent years as in previous NICE assessments [34].
2.4 Economic Analysis
The incremental cost-effectiveness ratio (ICER) was cal-
culated as the ratio of the mean incremental cost and the
mean number of incremental quality-adjusted life-years
(QALYs) for ranibizumab compared with either vPDT or
observation. Net monetary benefit (NMB) was calculated
assuming a willingness-to-pay of £20,000/QALY [38].
Using this formulation, higher NMB indicates greater
value: NMB greater than £0 is equivalent to an ICER of
less than £20,000/QALY. Thus, in the context of this
analysis, ‘cost effective’ is defined as meeting accepted
standards of cost effectiveness based on a willingness-to-
pay threshold of £20,000/QALY. Deterministic sensitivity
analysis was used to explore uncertainty around individual
input values to the model, and the effect on the resultant
NMB calculated. Probabilistic sensitivity analysis was used
to assess the overall level of uncertainty in the model (see
ESM, Online Resource 7 for parameters and distributions).
The internal validity of the model was checked by a health
economist not involved in the development or use of the
model. Face validity of the model was validated by two UK
ophthalmologists.
3 Results
The model predicted that the gain in BCVA in year 1 was
greater with ranibizumab than with vPDT (in agreement
with the trial data); for both treatments, BCVA gradually
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decreased over subsequent years (Fig. 2). The number of
life-years gained was slightly higher with ranibizumab than
with vPDT or observation (difference of 0.15 and
0.24 years, respectively), reflecting the higher mortality in
patients with low BCVA. Ranibizumab was associated
with a QALY gain of 0.39 over vPDT and a QALY gain of
0.54 over observation (Table 3). Lifetime costs were
slightly lower for ranibizumab than for vPDT (-£1,555)
but higher than for observation (?£4,703, Table 3). As
ranibizumab led to greater health gains at lower cost, it was
dominant over vPDT (Table 3). The NMB was £9,289 at a
willingness-to-pay threshold of £20,000/QALY. Compari-
son of ranibizumab with observation gave an ICER of
£8,778/QALY (Table 3), which is lower than the threshold
of £20,000–30,000/QALY often applied in the UK [38].
The NMB was £6,013.
There were differences in the cost of blindness between
treatments. The lifetime cost of blindness was lower for
patients receiving ranibizumab (-£3,920) or vPDT (-
2,138) than for patients under observation. Costs of AEs
incurred with ranibizumab (£106) or vPDT (£10) were
negligible and did not impact on the overall costs.
One-way sensitivity analysis showed that the model
results were robust. Comparing with vPDT (Fig. 3a), the
model was most sensitive to the maximum utility gain for
the WSE, with higher utility values increasing NMB. Ra-
nibizumab was cost effective even when assuming 12 ra-
nibizumab injections in the first year (NMB, £596) and
only ceased to be cost effective if 11 or more injections
were administered in year 2, or at a cost over £1,100 per
monitoring visit or a cost over £1,300 per injection visit at
the base case number of injections. Extensive variation of
the TPs in year 1 gave results that were consistent with the
base-case scenario. Comparing with observation (Fig. 3b),
the model was also sensitive to the maximum utility gain
for the WSE. Ranibizumab ceased being cost effective
when ten injections were administered in the first year, or
seven in year 2, or at a cost over £1,100 per monitoring
visit or a cost over £900 per injection visit.
The probabilistic sensitivity analysis showed that rani-
bizumab has a 100 and 88 % probability of being cost
effective compared with vPDT and observation, respec-
tively, at a willingness-to-pay threshold of £20,000/QALY
(Fig. 4). Validation of the model by detailed examination
of the Markov traces confirmed that the model produced
similar results to the study data on which it was based.
4 Discussion
This is the first study to evaluate the cost effectiveness of
ranibizumab compared with vPDT or observation for the
treatment of patients with visual impairment due to myopic
CNV. The analysis showed that ranibizumab is dominant
over vPDT and was associated with lower lifetime costs
and an incremental QALY gain. Ranibizumab was cost
effective compared with observation, with an ICER of
£8,778/QALY. One-way sensitivity analysis showed that
the model results were robust, but sensitive to the maxi-
mum utility gain for the WSE and number of ranibizumab
injections received. Probabilistic sensitivity analysis

























Fig. 2 Visual acuity modelled over time. BCVA best-corrected visual
acuity, ETDRS Early Treatment Diabetic Retinopathy study, vPDT
verteporfin photodynamic therapy
Table 3 Base-case cost-effectiveness results using deterministic values
Ranibizumab vPDT Observation Ranibizumab versus vPDT Ranibizumab versus observation
Cost (£) 12,866 14,421 8,163 -1,555 ?4,703
QALYs 12.99 12.60 12.45 ?0.39 ?0.54
Life-years 16.85 16.70 16.61 ?0.15 ?0.24
NMB (£) – – – 9,289 6,013
ICER (£/QALY) – – – Dominant 8,778
The model followed a cohort of 1,000 patients over a lifetime time horizon. The healthcare provider perspective was adopted. Future costs and
health outcomes were discounted at 3.5 % per annum
ICER incremental cost-effectiveness ratio, NMB net monetary benefit, QALY quality-adjusted life-year, vPDT verteporfin photodynamic therapy
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being cost effective compared with vPDT and observation,
respectively, at a willingness-to-pay threshold of £20,000/
QALY.
The anti-VEGF bevacizumab was not included as a
comparator in this analysis because it is unlicensed for the
treatment of myopic CNV and its use is not considered by
NICE to be routine practice across the NHS. Furthermore,
after reviewing the quality of evidence for bevacizumab in
myopic CNV, the NICE committee concluded that there
was insufficient evidence to allow bevacizumab to be
included with confidence in a clinical and cost-effective-
ness analysis [39].
The improvements in BCVA with ranibizumab com-
pared with vPDT in the RADIANCE study (?10.5 and
?10.6 letters, respectively, for the disease stabilization and
disease activity criteria groups at 3 months) translated to
higher utility values in the model, reflecting improved
HRQoL after treatment. This gain was achieved with rel-
atively few injections. In the ‘disease activity’ treatment
group, whose characteristics were incorporated into the
model and whose treatment corresponded to the rani-
bizumab myopic CNV label, 50 % of patients required 1–2
injections, 36 % required 3–5 injections and 14 % required
6–12 injections over the 12-month study [40]. This trans-
lated into a mean treatment frequency of 3.5 ranibizumab
injections in year 1 of the model. The 3.4 vPDT treatments
in year 1 were calculated from treatment frequency in the
large VIP trial [5, 6]. We used a very conservative
assumption of 8.5 monitoring visits in year 1, which is
likely to overestimate visits compared with clinical prac-
tice. In deterministic sensitivity analysis, increasing the
frequency of injections and follow-up visits had a strong
effect on the cost effectiveness. However, even assuming
12 injections in year 1, ranibizumab remained cost effec-
tive compared with vPDT given 3.4 times per year.
Myopic CNV is a relatively acute condition with a
reduced requirement for retreatment compared with other
retinal conditions such as neovascular age-related macular
degeneration; this is reflected in the low number of rani-
bizumab injections required in year 2. During the 12-month
follow-up in the RADIANCE study, over 50 % of patients
treated with ranibizumab according to disease activity
criteria required only 1–2 injections and over 60 % did not
require further injections from month 6 to month 12 [41].
The NICE review of the model suggested that 1.7 injec-
tions in year 2 would be a more reasonable assumption than
the one injection included in the model [39]. However, the
number of treatments in years 1 and 2 were varied in
deterministic and probabilistic sensitivity analyses and did
not affect the cost-effectiveness decision. Compared with
vPDT, ranibizumab only ceased to be cost effective if 11 or
more injections were administered in year 2. Compared
with observation, ranibizumab only ceased being cost
effective when seven or more injections were administered
in year 2.
The RADIANCE results were used to estimate BCVA
for year 1 for ranibizumab and for 0–3 months for vPDT as
patients from the vPDT arm were allowed to cross over
after 3 months to enable them to benefit from ranibizumab
treatment. Thus, data from the VIP trial were used to model
BCVA for patients receiving vPDT after 3 months, and the
placebo arm data were used to simulate patients under
observation only [6]. After 1 year, the decline in BCVA
was modelled with the same rate across treatments. This is
a conservative approach as recurrence after treatment is
likely to be more common in the vPDT group than with
ranibizumab [28]. The slow rate of decline in BCVA in
subsequent years is consistent with several studies showing
that visual acuity gains are maintained over 3–5 years in a
high proportion of patients treated with anti-VEGF therapy
[42–44]. Bilateral disease was only modelled by prevalence
as patients entered the model because accurate estimation
of the incidence rate was not possible owing to the lack of
long-term natural history data. Bilateral disease was
assumed to double the cost of treatment at the start of the
model; for recurrence, the additional costs occurred at the
time of the recurrence and included 1 year of treatment and
monitoring (overestimating what would happen in clinical
practice). Neither variations in the rate of recurrence
(0–12 %) nor the baseline rate of bilateral disease
(0–30 %) affected the dominance of ranibizumab over
vPDT. As the mean age of the cohort increased, rani-
bizumab became less cost effective compared with vPDT
or observation as cost savings from avoidance of blindness
were not realized.
Utility estimates for the BSE were obtained from a
published study that had simulated visual impairment
associated with age-related macular degeneration using
specially designed contact lenses [33]. BCVA was defined
for the BSE and the ‘health states’ valued by a represen-
tative sample of the UK population using the time trade-off
technique [33]. The resultant utility values were adjusted to
control for important factors known to affect utility
(including age and sex). NICE has previously judged that,
in the absence of studies reporting utility values for the
specific ocular condition, these utility values most accu-
rately reflect the HRQoL associated with visual impairment
[34]. The 5-domain European Quality of Life questionnaire
was used in the RADIANCE study but the results were not
used in the present analysis as the instrument is acknowl-
edged as being insensitive to changes in visual acuity [13].
In sensitivity analysis, varying the utility values by a factor
of 0.3–1.3 had little effect on the overall results.
The relationship between utility and BCVA in the WSE
is a major source of uncertainty and there are no published
studies that can be used to estimate utilities in the WSE.
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Our approach was to assume that utilities would be the
same for the BSE and WSE in the highest BCVA health
state, while for all other BCVA health states, utilities for
the WSE would be proportional to but higher than utilities
for the BSE, with the greatest difference between the BSE
and WSE at the lowest BCVA health state. Essentially,
visual impairment in the BSE has a greater negative effect
on utility than impairment in the WSE. This is supported
by visual functioning findings [35]. In the base case there
was a 0.1 maximum difference in utility values for the
WSE between the best and worst possible health states, as
good binocular vision is considered ‘worth’ an additional
utility of 0.1 compared with good vision in only one eye
[34]. In sensitivity analyses, the maximum utility gain in
Utility curve for WSE (0.05–0.6)
Unit cost of vPDT (£0–£3000)
Unit cost of ranibizumab (£0–£3000)
vPDT injection frequency Y1 (0–12)
Cost of monitoring visit (£0–£1500)
vPDT injection frequency Y2 (0–12)
Cost of vPDT administration visit (£0–£1500)
Cost of ranibizumab administration visit (£0–£1500)
Ranibizumab injection frequency Y1 (0–12)
Ranibizumab injection frequency Y2 (0–12)
Discount rate – benefits (0%–5.50%)
Starting age (35–95 years)
Natural progression (multiplier: 0.5–2)
Utility curve for BSE (multiplier: 0.3–1.3)
vPDT transition probabilities – C1 (multiplier: 0.5–2)
Ranibizumab transition probabilities – C2 (multiplier: 0.5–2)
vPDT transition probabilities – C4 (multiplier: 0.5–2)
vPDT transition probabilities – C3 (multiplier: 0.5–2)
Ranibizumab transition probabilities – C4 (multiplier: 0.5–2)
Cost of blindness (multiplier: 0.5–2)
Ranibizumab transition probabilities – C3 (multiplier: 0.5–2)
Ranibizumab monitoring frequency Y1 (0–12)
vPDT monitoring frequency Y1 (0–12)
vPDT transition probabilities – C2 (multiplier: 0.5–2)
Ranibizumab monitoring frequency Y2 (0–12)
vPDT monitoring frequency Y2 (0–12)
Ranibizumab transition probabilities – C1 (multiplier: 0.5–2)
Probability that the study eye is the BSE (multiplier: 0.5–2)
Rate of recurrence (0%–12%)
Discount rate – costs (0%–5.50%)
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Fig. 3 Tornado plots showing results of one-way sensitivity analysis
for ranibizumab compared with a vPDT and b observation. The X axis
represents the net monetary benefit, which for the base-case scenario
is £9,289 for ranibizumab versus vPDT, and £6,013 for ranibizumab
versus observation. Parameters varied are listed in the Y axis. Low
value, lower limit of parameter varied for sensitivity analysis; high
value, upper limit of parameter varied for sensitivity analysis;
multiplier, multiplication factor for base-case value of parameter. BSE
better-seeing eye, vPDT verteporfin photodynamic therapy, WSE
worse-seeing eye
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the WSE had a bigger impact on the results than the other
parameters tested. For values of 0.5 or more, the WSE
actually had worse utility values than the BSE for the same
level of BCVA, which is counterintuitive. At these high
estimations, ranibizumab was more cost effective com-
pared with vPDT or observation than in the base-case
estimate. Varying the probability that the study eye was the
BSE had little effect on the dominance versus vPDT or cost
effectiveness versus observation.
Previous models using BCVA health states have main-
tained a constant proportion of patients whose treated eye
is their BSE over the period of the model. The current
model is dynamic in that, although the proportion of
patients whose treated eye is their BSE is fixed within a
health state, as patients transition across health states the
overall proportion whose treated eye is their BSE can
change over time in the model. Thus, for patients whose
treated eye is the WSE, if treatment improves the visual
acuity of the treated eye to such an extent that it exceeds
the BCVA of the fellow eye, the treated eye becomes the
BSE. This can appear counterintuitive, as higher visual
acuity in the treated eye may decrease the patient-level
utility value, but can be considered a conservative
approach as it would underestimate total QALY gain.
Furthermore, modelling both BSE and WSE allows more
accurate estimations of utility for the patient, reflecting the
relative gain from binocular vision.
The study was undertaken from a UK perspective and
used UK-specific costs; however, the trial data from the
RADIANCE study and VIP trial were international, and the
Utility curve for WSE (0.05–0.6)
Unit cost of ranibizumab (£0–£3000)
Cost of ranibizumab administration visit (£0–£1500)
Ranibizumab injection frequency Y1 (0–12)
Ranibizumab injection frequency Y2 (0–12)
Discount rate – benefits (0%–5.50%)
Cost of monitoring visit (£0–£1500)
Natural progression (multiplier: 0.5–2)
Rate of recurrence (0%–12%)
Cost of blindness (multiplier: 0.5–2)
Utility curve for BSE (multiplier: 0.3–1.3)
Observation transition probabilities – C3 (multiplier: 0.5–2)
Observation transition probabilities – C4 (multiplier: 0.5–2)
Starting age (35–95 years)
Probability that the study eye is the BSE (multiplier: 0.5–2)
Ranibizumab transition probabilities – C2 (multiplier: 0.5–2)
Observation transition probabilities – C2 (multiplier: 0.5–2)
Observation transition probabilities – C1 (multiplier: 0.5–2)
Ranibizumab transition probabilities – C4 (multiplier: 0.5–2)
Ranibizumab transition probabilities – C3 (multiplier: 0.5–2)
Ranibizumab monitoring frequency Y1 (0–12)
Ranibizumab monitoring frequency Y2 (0–12)
Ranibizumab transition probabilities – C1 (multiplier: 0.5–2)
Observation monitoring frequency Y1 (0–12)
Observation monitoring frequency Y2 (0–12)
Baseline prevalence of bilateral disease (0%–30%)
Discount rate – costs (0%–5.50%)
Low value
High value
Net monetary benefit (£)
–20,000 0 20,000 40,000 60,000
(b)
Fig. 3 continued
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efficacy and safety results are considered to have good
generalizability between populations and healthcare sys-
tems. Apart from treatment and visit-related costs, the
factors that had the greatest impact on the cost effective-
ness were unlikely to be country dependent. The effect of
increased mortality associated with low BCVA was not
tested in sensitivity analyses. However, the Evidence
Review Group on behalf of NICE conducted an exploratory
analysis that did vary the mortality multiplier for blindness
(BCVA B35 letters), with no effect on the cost-effective-
ness decision [39].
There is little previous work around the cost effective-
ness of treatments in myopic CNV. The one published
study in this indication compared vPDT and observation
from a US managed care perspective [45]. The base case
estimated a QALY gain of 0.037 and an ICER of
US$214,085/QALY over 1 year. The results are not com-
parable with the current study because of significant dif-
ferences in methodology, including a 1-year time horizon,
perspective and the absence of costs of blindness in the US
study. In wet age-related macular degeneration, diabetic
macular oedema and retinal vein occlusion, ranibizumab
has been shown to be cost effective (e.g. [34, 37, 46, 47]).
In summary, this economic evaluation shows that rani-
bizumab is dominant over vPDT and cost effective com-
pared with observation for the treatment of visual
impairment due to myopic CNV using a UK healthcare
perspective. This analysis suggests that ranibizumab should
be adopted in this patient population.
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